Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Kidney transplantation (KT) benefit-risk ratio assessment is a challenge in a growing population of older patients with end-stage kidney disease. A pre-KT frailty phenotype has been found predictive of post-KT complications, but biological mechanisms of frailty are poorly known is these patients. Frailty is associated with chronic low-grade inflammation in the older general population, possibly through the inflammasome pathway. Our main objective is to assess if systemic activation of inflammasomes is associated with frailty in older candidates to KT.
Kidney transplantation (KT) benefit-risk ratio assessment is a challenge in a growing population of older patients with end-stage kidney disease. Chronic low-grade inflammation is a hallmark of biological aging and is associated with age-related diseases and frailty. Frailty is conceptually defined as an agerelated reduction in physiological reserve increasing vulnerability to stressors. A pre-KT frailty phenotype is associated with post-KT complications, including re-hospitalizations, delayed graft function, delirium and 5-year mortality. Taking pre-KT inflammation into account (serum level of CRP, IL6, sTNFR1) improves prediction of mortality on KT waiting-list, independently of comorbidity.
Molecular and cellular pathways of this inflammation are poorly known, and may involve inflammasomes. Inflammasomes are intra-cellular protein complexes whose assembly, upon stress signals, triggers maturation and release of pro-inflammatory cytokines named interleukine (IL)-1 and IL-18. Inflammasomes are involved in locomotor, cognitive and immune aging in mice, and systemic expression of inflammasomes genes is associated with mortality in older humans. Data is lacking about systemic activation of inflammasomes in older patients with end-stage kidney disease. Our main objective is to assess if pre-KT systemic activation of inflammasomes is associated with frailty in older candidates to KT.
We will measure systemic activation of inflammasomes in peripheral blood of older candidates to KT using cytokine bead-based multiplex assay, Single Molecule Array, intra-cytoplasmic staining, flow cytometry and RT-qPCR in peripheral blood mononuclear cells. Frailty will be measured using validated standardized criteria. A frailty phenotype is defined by at least 3 of the following criteria:
weight loss, exhaustion, muscle weakness, low physical activity, low gait speed.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Frail Patients | Active Comparator | Frailty will be measured clinically using reference criteria in the general population and validated in Kidney Transplantation (KT), i.e. predictive of post-KT complications: delayed recovery of graft function, graft function, early re-hospitalization, occurrence of post-operative confusion, mortality. Fragile patients present at least 3 out of 5 criteria |
|
| non frail patients | Active Comparator | Patients will be considered non-fragile if they present 0 to 2 criteria |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood sample | Biological |
|
| Measure | Description | Time Frame |
|---|---|---|
| IL1 | Single Molecule Array for IL1 | at recruitment (up to 30 days) |
| IL18 | LUMINEX for IL18 in patient's sera | at recruitment (up to 30 days) |
| inflammasomes genes | RT-qPCR for inflammasomes genes (NLRP3, NLRC4, NLRC5, AIM2, ASC, casp1, IL1b, IL18) expression among peripheral blood mononuclear cells | at recruitment (up to 30 days) |
| inflammasome platform | Assembly of the inflammasome platform will be measured in monocytes using intra-cellular staining of the ASC protein and flow cytometry | at recruitment (up to 30 days) |
| Weight | Frailty phenotype : Weight loss (unintentional, >4,5 kg during past year) | at enrollment (Day 0), at recruitment (up to 30 days) |
| Activity | Frailty phenotype : Physical activity <383 kcal/week (men) or <270 kcal/week (women), measured using a standardized questionnaire (IPAQ) | at enrollment (Day 0), at recruitment (up to 30 days) |
| Gait | Frailty phenotype : 4-meters gait speed, with sex and height-specific cutoffs | at enrollment (day 0), at recruitment (up to 30 days) |
| Handgrip strength |
| Measure | Description | Time Frame |
|---|---|---|
| Comorbidity | Comorbidity : Cumulative Illness Rating Scale (CIRS-G score) | at recruitment (up to 30 days) |
| decline | Screening for intrinsic capacity decline : first step of ICOPE program, adapted to the study |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Florent GUERVILLE, MD | Contact | 05 57 65 65 53 | +33 | florent.guerville@chu-bordeaux.fr |
| Name | Affiliation | Role |
|---|---|---|
| Florent GUERVILLE, MD | University Hospital, Bordeaux | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Bordeaux - Hôpital Pellegrin - | Bordeaux | France | 33076 | France |
Not provided
| ID | Term |
|---|---|
| D007676 | Kidney Failure, Chronic |
| D000073496 | Frailty |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D051436 | Renal Insufficiency, Chronic |
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Geriatric assessment standardized | Behavioral |
|
|
Frailty phenotype : Handgrip strength, measured using a dynamometer, with sex and BMI-specific cutoffs |
| at enrollment (day 0), at recruitment (up to 30 days) |
| at recruitment (up to 30 days) |
| Physical performance | Physical performance : Short Physical Performance Battery (SPPB) score. The SPPB (Short Physical Performance Battery) is the sum of scores on three criteria: the balance test, the walking speed test and the chair lift test. This test assesses an individual's physical performance. The sum of the scores for all the tests gives an overall performance score. A score below 8 indicates a risk of sarcopenia (or age-related muscular dystrophy). | at recruitment (up to 30 days) |
| Cognitive functions | Cognitive functions : Score Montreal Cognitive Assessment (MoCA) score The Montreal Cognitive Assessement (MoCA) is the most sensitive rapid assessment test, providing the most comprehensive evaluation (attention, concentration, executive functions, memory, language, capacitive-vesuo-constructive, abstraction, calculation, orientation) cognitive functions. It is tending to replace the MMSE in clinical practice. A score of 26 (25 if cultural level ≤3 = primary diploma = CEP) is considered abnormal. | at recruitment (up to 30 days) |
| Depression | Depression : Geriatric Depression Scale (GDS-15 score) 0 - 5 points: normal 5-10 points: mild to moderate depression 11-15 points: severe depression | at recruitment (up to 30 days) |
| Nutrition | Nutrition : Mini Nutritional Assessment (MNA score)
| at recruitment (up to 30 days) |
| Snellen test | Sensory functions : Snellen test for vision | at recruitment (up to 30 days) |
| ADL | Dependency in activities of daily living : Activities of Daily Living ADL The original ADL scale scores each of the 6 items in 0/1, with 1 corresponding to independence and 0 to dependence. The total score ranges from 0 to 6. An overall score can be calculated, ranging from 0 (totally dependent) to 6 (best possible independence). | at recruitment (up to 30 days) |
| Immunophenotyping | Immunophenotyping of peripheral lymphocytes, with a focus on proportions of naïve / central memory / effector memory / TEMRA cells, and markers of activation and senescence | at recruitment (up to 30 days) |
| CRP | Serum inflammatory markers : CRP | at recruitment (up to 30 days) |
| IL-6 | Serum inflammatory markers : IL-6 | at recruitment (up to 30 days) |
| MCP-1 | Serum inflammatory markers : MCP-1 | at recruitment (up to 30 days) |
| TNF | Serum inflammatory markers : TNF | at recruitment (up to 30 days) |
| sTNFR1 | Serum inflammatory markers : sTNFR1 | at recruitment (up to 30 days) |
| HHIES questionnaire | Sensory functions : Hearing Handicap Inventory for the Elderly Screening (HHIES) questionnaire for hearing. The higher the score, the greater the likelihood of hearing loss | at recruitment (up to 30 days) |
| IADL | Dependency in activities of daily living : IADL scores | at recruitment (up to 30 days) |
| CHU de Bordeaux, Hôpital Xavier Arnozan- Gérontologie Clinique | Pessac | France | 33600 | France |
|
| CHU de Toulouse - Hôpital Rangueil | Toulouse | France | 31059 | France |
|
| D052776 |
| Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |